SALT
LAKE CITY, Nov. 15, 2024 /PRNewswire/ -- Sera
Prognostics Inc., The Pregnancy Company®
(NASDAQ: SERA), focused on improving maternal and neonatal health
by providing innovative pregnancy biomarker information to doctors
and patients, today announced that the company will present at the
Canaccord Genuity MedTech, Diagnostics and Digital Health &
Services Forum on November 21, 2024
at 4:00 p.m. ET. Zhenya
Lindgardt, President and CEO, will participate in a fireside chat
and provide a company update and discuss Sera's latest
achievements.
A live webcast of the company's presentation as well as a
webcast replay will be available online from the Investors page of
the Company's website at www.seraprognostics.com.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company
dedicated to improving the lives of women and babies through
precision pregnancy care. Sera's mission is to provide early,
pivotal pregnancy information to improve the health of mothers and
newborns, resulting in reductions in the costs of healthcare
delivery. Sera has a robust pipeline of innovative diagnostic tests
focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera's precision medicine
PreTRM® Test reports to a physician the individualized
risk of spontaneous premature delivery in a pregnancy, enabling
earlier proactive interventions in women with higher risk. Sera
Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation
and is the leading cause of illness and death in newborns. The 2023
March of Dimes Report Card shows that, for the last five
consecutive years, more than one in ten infants is born prematurely
in the United States. Prematurity
is associated with a significantly increased risk of major
long-term medical complications, including learning disabilities,
cerebral palsy, chronic respiratory illness, intellectual
disability, seizures, and vision and hearing loss, and can generate
significant costs throughout the lives of affected children. The
annual health care costs to manage short- and long-term
complications of prematurity in the United States were
estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated,
commercially available blood-based biomarker test that provides an
early, accurate and individualized risk prediction for spontaneous
preterm birth in asymptomatic singleton pregnancies. The
PreTRM® Test measures and analyzes proteins in the blood
that are highly predictive of preterm birth. The PreTRM®
Test permits physicians to identify, during the weeks 18 through 20
of pregnancy, which women are at increased risk for preterm birth
and its complications, enabling more informed, personalized
clinical decisions based on each woman's individual risk. The
PreTRM® Test is ordered by a medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy
Company, and PreTRM are trademarks or registered trademarks of Sera
Prognostics, Inc. in the United States and/or other
countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the date, time, content and
webcast replay availability of the Company's presentation at the
Canaccord Genuity MedTech, Diagnostics and Digital Health &
Services Forum; and the company's strategic directives under the
caption "About Sera Prognostics, Inc." These "forward-looking
statements" are based on management's current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by forward-looking
statements. These risks and uncertainties include, but are not
limited to: net losses, cash generation, and the potential need to
raise more capital; revenues from the PreTRM Test representing
substantially all Company revenues to date; the need for broad
scientific and market acceptance of the PreTRM Test; a concentrated
number of material customers; our ability to introduce new
products; potential competition; our proprietary biobank; critical
suppliers; the COVID-19 pandemic and its potential lingering impact
on our operations, as well as the business or operations of third
parties with whom we conduct business; estimates of total
addressable market opportunity and forecasts of market growth;
potential third-party payer coverage and reimbursement; new
reimbursement methodologies applicable to the PreTRM Test,
including new CPT codes and payment rates for those codes; changes
in FDA regulation of laboratory-developed tests; the intellectual
property rights protecting our tests and market position; and other
factors discussed under the heading "Risk Factors" contained in our
Final Prospectus on Form S-1, which was filed with the Securities
and Exchange Commission on July 14,
2021, as well as any updates to those risk factors filed
from time to time in our Quarterly Reports on Form 10-Q, Annual
Reports on Form 10-K, or Current Reports on Form 8-K. All
information in this press release is as of the date of the release,
and the Company undertakes no duty to update this information
unless required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-present-at-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302306471.html
SOURCE Sera Prognostics, Inc.
